{"name":"Glyscend, Inc.","slug":"glyscend-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxQZER0RVhCSzRzdnJaTVdzVmVlaHVBNDRpbVJHZFJ5TXUyUTBfekJEaTdKeXI3eU9zbzNUckIxbVpwRGpjOTY3ZVI1bUJ1RE5PS0dzdllMTXVaSFQ2MzRpVEpUU2locXdsN0hab1hiRjB6Z3VJZDNaMmJEUFR6dElwMjEwNlpDUE15Unh4RlBtRzZZUkEweVBQWXNmbTJocUlTLVBiUHJocEdTUzJZQTZuaDNJZ1hUYUNEVUFvbXhtd1JITm5yNFBjOXJBcEc1ZzlDSWNubnNjMXRPTFZPUFMwalVWOEJFU19XQ2Fha0VMSjl5bV9pcm5YZWMzLUhlVjdVTXVGLThWcHA2X0xFbV9MQTQ5RjJLMHZ6NklsN2NDb3ctVVg5ZXBOZ0VEOUtCWm5abzFZ?oc=5","date":"2024-06-03","type":"trial","source":"Business Wire","summary":"Glyscend Doses First Patient in a Phase 2 Obesity Trial of GLY-200, a First-in-Class Oral Polymeric Drug Candidate for the Treatment of Metabolic Disease - Business Wire","headline":"Glyscend Doses First Patient in a Phase 2 Obesity Trial of GLY-200, a First-in-Class Oral Polymeric Drug Candidate for t","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE9EUkxPZjVQMnJ2VDk0aEthQm5qc0dET2xNN3lpbU5NTF9qWGJFdHhDRUN4YmhTdkY4T0xhZ1ZiYmt4UklEdjFVRmJnejNHU0ZyZVZCclpvbzhkWGFkbUo4QXJ4ekxjYm51aVJfLXVSc3NTRjg?oc=5","date":"2023-11-21","type":"pipeline","source":"Labiotech.eu","summary":"Beyond insulin: six cutting-edge diabetes biotech companies you should know about - Labiotech.eu","headline":"Beyond insulin: six cutting-edge diabetes biotech companies you should know about","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNZEgzdGhSMXo2S28tR1M5VVZaMVRRSkNZeDgyR2RnNDBUeVNrRGZDeVIycTFxRHBPdGFOdm5INmpUaEYtYjBZSVJjQjhqMnRVVGxTN19GM3F3UEVIN1kxNlVKSWc3bHRYUlZHVTRjckxMcElSeGk0VkJyZXY2aXdRTktXVk5sVTdRbGJmVjVsSnlITEJGZlFR?oc=5","date":"2023-05-31","type":"trial","source":"BioSpace","summary":"Glyscend’s First-in-Class Oral Diabetes Drug Shows Phase II Promise - BioSpace","headline":"Glyscend’s First-in-Class Oral Diabetes Drug Shows Phase II Promise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxPeUZuYzNxQTliTXp3eWNwTTFtMm9RanJSc1M3WFA5YWw2UGp4Q1hMSHQ1cm5mSkZUZ09tNWloRk45eUU0bXN0eGU2R3hYdndSR0N6T3V4WG5sNUI0Y242RmFxTFNYYTNCYjhPa19jUEgyWEtsS3FfeHhUZjd3ZGxUWElrdlVNbkRkdVZ2X2QxUmdvZTc2Z2Z4V1ctRlJvS1BpTkV3WmZDQ2k4RWwwSnV4SHNNQ2N2Y1BJLVZNMHQ3LXU1WHFVcmRIbnNPckFGQVQtRVQ1al9DQkJSMTVfd1I3bW03WDlTLWpYWTZuakNFTUZ6d1VEUlQ1QWJRbXYzeGpzcVZqeGlxcmNQMU83THhsOW1FWjN5bTNWVXNSVW1MS0wzLWZaOGppTGlXTkZYSnF4eWxKcTY1cU5pRXVF?oc=5","date":"2023-05-31","type":"trial","source":"Business Wire","summary":"Glyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class Treatment for Type 2 Diabetes and Obesity - Business Wire","headline":"Glyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class T","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}